Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)" aimed at supporting multidisciplinary research to enhance technologies for infertility treatment, particularly through Assisted Reproductive Technologies (ART). This initiative seeks to fund innovative projects that lead to the development of validated technologies, with a phased award structure allowing for up to five years of support—two years for the exploratory R61 phase (no clinical trials) and up to three years for the developmental R33 phase (clinical trials permitted). The NIH plans to allocate $3.3 million in FY 2026 to fund up to 11 R61 awards, with the potential for up to 7 projects to transition to the R33 phase. Interested applicants can find more information and application details at the provided link and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for November 20, 2025.
Eligible Applicants
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.